Irritable Bowel Syndrome News

SAN DIEGO — Enterosgel, a CE-certified intestinal absorbent, reduced short-term symptoms of stool consistency and abdominal pain among patients with irritable bowel syndrome with diarrhea, according to research.

Nearly half of the respondents in Salix Pharmaceutical’s annual patient perspective survey reported it was more challenging to manage their irritable bowel syndrome and chronic idiopathic constipation symptoms during the last 12 months.

April is IBS Awareness Month and highlights the importance of public awareness and health messages about the diagnosis, treatment and quality of life for patients with irritable bowel syndrome.

According to the International Foundation for Gastrointestinal Disorders, irritable bowel syndrome is estimated to effect 10% to 15% of the population worldwide, making it the most prevalent functional GI disorder.

This month’s cover story focuses on the integrated, team-based approach to managing patients with irritable bowel syndrome.

Open-label placebo reduced pain and rescue medication use among pediatric and adolescent patients with functional abdominal pain and irritable bowel syndrome, according to research published in JAMA Pediatrics.

A short-term, moderately low FODMAP diet, in addition to a strict gluten-free diet, significantly reduced gastrointestinal symptoms and improved disease-specific health in celiac patients, according to a study.

A single dose of Relistor injection produced rescue-free laxation in severely ill patients with opioid-induced constipation who had an insufficient response to laxative therapy, according to a study published in the Journal of Emergency Medicine.

Healio Gastroenterology presents the following report on the top 10 peer-tested stories from 2021.

Healio Gastroenterology presents the following report on the top 10 peer-tested articles from November 2021.